Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
Phase 2 – studying effectiveness and dosage
Conditions:
Chronic Kidney Disease
Sponsor: Universitair Medisch Centrum Groningen
trial.available_in:
БГ
Overview
Trial status: Authorised
Change from baseline to week 36 in eGFR (creatinine, cystatin C, and creatinine-cystatin C), Change from baseline to week 36 in Iohexol measured GFR (subset of 60 participants), Change in UACR and eGFR during 4-week wash-out from week 36 to 40, Change from baseline to week 36 in Perirenal and renal sinus fat measured by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Subcutaneous and visceral fat assessed by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Body weight, Change from baseline to week 36 in Waist circumference, Change from baseline to week 36 in Systolic and diastolic blood pressure
Percentage change from baseline to week 32/36 in first morning void UACR
Description
Change from baseline to week 36 in eGFR (creatinine, cystatin C, and creatinine-cystatin C), Change from baseline to week 36 in Iohexol measured GFR (subset of 60 participants), Change in UACR and eGFR during 4-week wash-out from week 36 to 40, Change from baseline to week 36 in Perirenal and renal sinus fat measured by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Subcutaneous and visceral fat assessed by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Body weight, Change from baseline to week 36 in Waist circumference, Change from baseline to week 36 in Systolic and diastolic blood pressure
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 50 participants
БГ